Initiation of the clin­i­cal trial triggers $50 million mile­stone pay­ment from AbbVie

South San Francisco, CA (Press Release) – Harpoon Thera­peutics, Inc. (NASDAQ: HARP), a clin­i­cal-stage immuno­therapy com­pany devel­op­ing a novel class of T cell engagers, to­day announced that the first patient has been dosed with HPN217 in a Phase 1/2 clin­i­cal trial focused on re­lapsed, re­frac­tory multiple myeloma (RRMM). HPN217 is being devel­oped under a global license and option agree­ment with AbbVie Inc. (NYSE:ABBV) and dosing of the first patient in a clin­i­cal trial has triggered a $50 million mile­stone pay­ment to Harpoon. HPN217 targets B-cell maturation an­ti­gen (BCMA), a well-validated an­ti­gen ex­pressed …

• Harpoon grants AbbVie option to license world­wide rights to HPN217 (BCMA), a TriTAC for the treat­ment of multiple myeloma planned for IND filing this year
• Expanded TriTAC discovery col­lab­o­ration in­cludes up to six addi­tional targets selected by AbbVie
• Two agree­ments provide for a total of $50 million in up­front and up to $50 million in a contingent mile­stone pay­ment for first patient treated with HPN217 in a clin­i­cal trial

South San Francisco, CA and North Chicago, IL (Press Release) – Harpoon Thera­peutics, Inc. (NASDAQ: HARP), a clin­i­cal-stage immuno­therapy com­pany devel­op­ing a novel class of T cell engagers, and AbbVie Inc. (NYSE: ABBV), a global bio­pharma­ceu­tical com­pany, today announced an ex­clu­sive world­wide option and license trans­action for HPN217, Harpoon’s B cell maturation an­ti­gen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC®), and an ex­pan­sion of their existing discovery col­lab­o­ration for up to six addi­tional targets. These agree­ments build upon the …